Web Results


Sep 4, 2016 ... Gavel About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Horizon Therapeutics, Inc. v. Lupin Ltd. et al. 1:16-cv- 04438; ... Plaintiffs: AstraZeneca AB; Aktiebolaget Hassle; AstraZeneca LP; Zeneca Inc. ... Defendants: Lallemand Specialties, Inc.; Mascoma LLC.


Sep 4, 2016 ... AstraZeneca AB et al. v. Aurobindo Pharma Ltd. et al. 3:16-cv-04414; filed July 20 , 2016 in the District Court of New Jersey. • Plaintiffs: AstraZeneca AB; Aktiebolaget Hassle; AstraZeneca LP; Zeneca Inc. • Defendants: Aurobindo Pharma Ltd.; Aurobindo Pharma USA Inc. Infringement of U.S. Patent Nos.


Jul 14, 2008 ... Counsel information for Teva was not immediately available. The patent in suit is U.S. Patent Number RE37,314. The suit is AstraZeneca Pharmaceuticals LP et al. v. Teva Pharmaceuticals USA, case number 1:08-cv-00426-UNA in the U.S. District Court for the District of Delaware. The MDL is number 1949 ...


Welcome to AstraZeneca United States. Beginning its journey in 1953, AstraZeneca became one of the first pharmaceutical companies operating in the United States ...


Publications. Our innovative science means a strong track-record of publication in peer-reviewed journals, contributing to the foundation of scientific advancement. View our publications. We have ...


Aug 26, 2008 ... Nicotinic acetylcholine receptors (nAChRs) are promising drug targets in the treatment of several CNS disorders such as Alzheimer's disease, schizophrenia, neuropathic pain and substance abuse (Arneric et al., 2007). Successful treatments will require discovery of agents that select among multiple ...


Oct 16, 2007 ... Present address: AstraZeneca Pharmaceuticals LP, Hayward, CA. Scott L. Klakamp .... 86: 484-488. Confirmation on the immunogenicity assay used in the SB4 phase III study: response to the comments by Meacci et al .... Joseph S. Zakhari , Eric P. Zorrilla , Bin Zhou , Alexander V. Mayorov , Kim D. Janda.